Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MAD0004J08 in Healthy Adults
NCT04932850Phase 1Completed
- Sponsor
- Toscana Life Sciences Sviluppo
- Start
- Mar 2021
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MAbCo19 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Toscana Life Sciences Sviluppo. Primary endpoint: Severe/serious treatment-emergent adverse events. Started Mar 2021; status: completed.
02
Drugs
MAbCo19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04932850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04932850.